132831-06-2

Basic information

• Product Name: methyl (R*)-2-phenyl-2-((S*)-piperidin-2-yl)acetate
• CAS NO: 132831-06-2
• Molecular Weight: 233.31
• Mol File: 132831-06-2.mol

Chemical Properties

• CAS DataBase Reference: methyl (R*)-2-phenyl-2-((S*)-piperidin-2-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (R*)-2-phenyl-2-((S*)-piperidin-2-yl)acetate(132831-06-2)
• EPA Substance Registry System: methyl (R*)-2-phenyl-2-((S*)-piperidin-2-yl)acetate(132831-06-2)

Safety Data

• Hazardous Substances Data: 132831-06-2(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 19395-41-6 Ritalinic acid 
• 110-89-4 piperidine 
• 22979-35-7 Methyl phenyldiazoacetate 
• 460356-15-4 (Z)-3-Amino-7-methanesulfonyloxy-2-phenyl-hept-2-enoic acid methyl ester 
• 560132-18-5 Phenyl-piperidin-(2Z)-ylidene-acetic acid methyl ester 
• 32346-07-9 (Z)-(1-methoxy-2-phenylvinyloxy)trimethylsilane 
• 460356-12-1 methanesulfonic acid 4-cyano-butyl ester 
• 2427-16-9 5-hydroxy-pentanenitrile 
• 75844-69-8 t-butyl piperidinecarboxylate 
• 505-18-0 2,3,4,5-tetrahydropyridine 
• 101-41-7 benzeneacetic acid methyl ester 
• 110-87-2 3,4-dihydro-2H-pyran 
• 2629-91-6 7-phenyl-1-azabicyclo[4.2.0]octan-8-one 

Downstream Products

• 298-59-9 methylphenidate hydrochloride 
• 1382859-13-3 dl-threo-ritalinic acid hydrochloride 

Relevant articles and documents

Short synthesis of methylphenidate and its p-methoxy derivative

A short method for the preparation of racemic threo- and erythromethylphenidate derivatives is described. Condensation between α- ethoxy carbamate 1 and silyl ketene acetals 2a-b in the presence of TESOTf (20 mol%) afforded a 1.5:1 mixture of carbamates 3a-b/4a-b. Hydrogenolysis in EtOH followed by treatment with 3N HCl/MeOH afforded the corresponding hydrochlorides 7a-b/8a-b in good yields.

α-C-H Bond Functionalization of Unprotected Alicyclic Amines: Lewis-Acid-Promoted Addition of Enolates to Transient Imines

Enolizable cyclic imines, obtained in situ from their corresponding lithium amides by oxidation with simple ketone oxidants, are readily alkylated with a range of enolates to provide mono- and polycyclic β-aminoketones in a single operation, including the natural product (±)-myrtine. Nitrile anions also serve as competent nucleophiles in these transformations, which are promoted by BF3 etherate. β-Aminoesters derived from ester enolates can be converted to the corresponding β-lactams.

Methylphenidate, right pai methyl ester preparation method, intermediate and preparation method

The invention discloses preparation methods of methylphenidate and dexmethylphenidate, intermediates and preparation methods of the intermediates. The invention provides the preparation method of the methylphenidate, wherein the preparation method is any one of the following methods: a first method comprises the following steps of in a solvent, carrying out an amino protecting group removal reaction of a compound 4 with an amino de-protection reagent, and thus obtaining the methylphenidate 5; a second method comprises the following steps of under the action of an alkali, carrying out an intramolecular nucleophilic substitution reaction of a compound 11 to obtain the methylphenidate 5; and a third method comprises the following steps of in a closed system, in a solvent, under a palladium on carbon or palladium carbon hydroxide catalytic condition, carrying out a reaction of a compound 9 with hydrogen, to obtain the methylphenidate 5. The synthesis method has the advantages of short steps, cheap and easily obtained raw materials, high product yield, good chiral purity, low production cost, and good atomic economy, and is suitable for industrialized production.

ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER

A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.

Studies on the Eschenmoser coupling reaction and insights on its mechanism. Application in the synthesis of Norallosedamine and other alkaloids

The conditions of the Eschenmoser coupling reaction were studied. The formation of the α-thioiminium ion was achieved faster in the presence of an additive (NaI) and dry chloroform as the preferred solvent. The developed conditions were used for the second part of the reaction (the sulfur extrusion itself). The present protocol avoids the formation of byproducts, which were previously described as a major drawback to be overcome. Electrospray ionization tandem mass spectrometry was used to characterize some aspects (intermediates) of the first step of the reaction mechanism. Some reduction conditions were properly tested and the selected conditions were applied to the synthesis of the natural alkaloid Norallosedamine and other derivatives.

Process for the preparation of threo-methylphenidate hydrochloride

The present invention provides a process for the preparation of threo-methylphenidate hydrochloride. According to a preferred embodiment, the process comprises the following steps: (a) contacting 1-(phenylglyoxylyl)piperidine arenesulfonylhydrazone of the formula wherein Ar denotes an aryl group, where the aryl group may be substituted by a C1-C6 alkyl, halo or nitro group; with an inorganic base in the presence of a water immiscible organic solvent and a phase transfer catalyst to obtain (R*,R*)-enriched 7-phenyl-1-azabicyclo[4.2.0]octan-8-one of the formula: (b) reacting the (R*,R*)-enriched 7-phenyl-1-azabicyclo[4.2.0]octan-8-one prepared in step (a) with a solution of hydrogen chloride in methanol to obtain threo-enriched methylphenidate hydrochloride; (c) crystallizing the threo-enriched methylphenidate hydrochloride prepared in step (b) to give the desired threo-methylphenidate hydrochloride. Preferably, the threo-methylphenidate hydrochloride produced by the process of the present invention contains no more than 1% of the erythro-isomer.

Process for the preparation of dexmethylphenidate hydrochloride

The present invention provides a new and efficient process for the preparation of the dexmethylphenidate hydrochloride with high optical purity, the process comprising: (a) reacting a solution of threo-N-Boc-ritalinic acid with (S)-1-phenylethylamine, separating precipitated solid salt of (R,R)-enriched N-Boc-ritalinic acid with (S)-1-phenylethylamnine from the reaction mixture and recrystallizing, reslurring and/or trituring of said salt; (b) mixing the solid salt of (R,R)-N-Boc-ritalinic acid and (S)-1-phenylethylamine obtained in step (a) with aqueous acid and separating (R,R)-N-Boc-ritalinic acid from the mixture; and (c) reacting the (R,R)-N-Boc-ritalinic acid prepared in step (b) with hydrogen chloride and methanol to give dexmethylphenidate hydrochloride with optical purity of at least 99% ee. The present invention further provides salt of (R,R)-N-Boc-ritalinic acid with (S)-1-phenylethylamine as new intermediate in the preparation of dexmethylphenidate hydrochloride.

Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites

The rhodium(II)-catalyzed intermolecular C-H insertion of methyl aryldiazoacetates with either N-Boc-piperidine or N-Boc-pyrrolidine followed by deprotection with trifluoroacetic acid is a very direct method for the synthesis of methylphenidate analogues. By using either dirhodium tetraacetate or dirhodium tetraprolinate derivatives as catalyst, either the racemic or enantioenriched methylphenidate analogues can be prepared. The binding affinities of the methylphenidate analogues to both the dopamine and the serotonin transporters are described. The most notable compounds are the erythro-(2-naphthyl) analogues which display high binding affinity and selectivity for the serotonin transporter.

A concise and stereoselective synthesis of (+/-)-erythro-methylphenidate

A concise and stereoselective synthesis of racemic erythro-methylphenidate (1) is described. The coupling reaction between piperidine-2-thione (3) and 2-bromo-2-phenylmethylacetate (4) afforded the β-enaminocarbonyl compound 2 in 60% yield by a modified Eschenmoser sulfide contraction reaction. In most cases the bicyclic thiazolidinone 5 was produced. Diastereoselective reduction of 2 in the presence of borohydrydes furnished the (+/-)-erythro-methylphenidate in good yields with dr >95%.

Synthesis and pharmacology of site specific cocaine abuse treatment agents: A new synthetic methodology for methylphenidate analogs based on the Blaise reaction

In order to make new analogs of the dopamine (DA) uptake inhibitor methylphenidate, a synthetic methodology based on the Blaise reaction was developed. The reaction between α-bromophenylacetic acid esters, zinc and α-cyano-ω-mesylates gave stable primary enamines. After reduction of the enamines with cyanoborohydride, the amines could be cyclized to methylphenidate analogs in which the amine ring size and aromatic ring were varied. These compounds were tested for inhibitory potency against [3H]WIN 35,428 binding to the cocaine recognition site and [3H]DA uptake using rat striatal tissue. When the heterocyclic ring size was varied, the six-membered ring of methylphenidate appeared to be the optimum ring size. When the aryl ring was varied the 4-trifluoromethylphenyl analog was less potent than methylphenidate, the β-naphthyl congener was considerably more potent, whereas the α-naphthyl congener was less potent. Most of the compounds tested had ratios of uptake to binding inhibition (discrimination ratio) that were similar to cocaine and were therefore not lead compounds for the development of cocaine antagonists.